Livatag®

Onxeo files application for key Livatag® patent — Onxeo indleverer ansøgning om vigtigt patent for Livatag®

Potential expansion of Livatag IP estate to extend commercial exclusivity through 2036 Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of drugs for orphan oncology diseases, today announced that it has filed an international patent application to protect the overall compound related to its primary liver cancer orphan oncology product Livatag®. The patent…read more →

Update on ReLive, Livatag® international phase III clinical trial in HCC – 50% patients randomized – Opdatering om ReLive, det internationale kliniske fase III-studie med Livatag® til behandling af leverkræft 50% patienter randomiseret

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, updates on the clinical development status of ReLive , the Livatag® phase III trial  in the treatment of hepatocellular carcinoma. Livatag®, a new therapeutic approach for hepatocellular carcinoma Livatag® is based on the innovative « Transdrug ™ » technology  designed to formulate a chemotherapy (doxorubicin)…read more →

ReLive: investigators meeting and E-poster of the study design during the 2015 EASL congress -ReLive: Investigator-møde og e-poster om studiets design under 2015 EASL-kongressen

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that  an investigators’ meeting (on April 24, 2015) will be held during the 50th annual meeting of the European Association for the Study of the Liver (EASL) taking place in Vienna (Austria) from April 22 to April 26, 2015, with…read more →

Onxeo announces 6th positive DSMB recommendation for Livatag® ReLive study in HCC – Onxeo offentliggør den sjette positive anbefaling fra ekspertkomité for ReLive-studiet med Livatag® mod primær leverkræft

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the independent European board of experts, the Data Safety Monitoring Board (“DSMB”), which monitors the safety of the Livatag® phase III trial, “ReLive”, has once again unanimously recommended to continue the study without modification. ReLive is an international, randomized…read more →

Onxeo expands Livatag® international phase III clinical trial “ReLive” to 3 new countries – Onxeo udvider det internationale kliniske fase III-studie med Livatag® (“ReLive”) til tre nye lande

Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that Livatag® phase III clinical trial “ReLive” is expanded to  3 new countries in the Middle-East and North Africa region (MENA). The ReLive study is an international phase III trial designed to assess Livatag®’s (Doxorubicin Transdrug™) efficacy on survival in…read more →

Onxeo announces positive DSMB recommendation for its Phase III trial with Livatag® in primary liver cancer – Onxeo offentliggør positiv anbefaling fra ekspertkomité for selskabets fase III-studie med Livatag® mod primær leverkræft

Onxeo SA (Euronext Paris, NASDAQ OMX Copenhagen – ONXEO), an innovative company specializing in the development of orphan oncology drugs, today announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) in charge of the safety monitoring of the Livatag® Phase III trial has once again unanimously recommended continuing the study without modification. “Each new positive…read more →

Onxeo reaches second milestone of BPIFrance grant dedicated to Livatag® development as part of NICE Consortium – Onxeo modtager den anden milepælsbetaling af BPIFrance-tilskuddet til udviklingen af Livatag® som led i NICE-konsortiet

Onxeo S.A. (Euronext Paris, NASDAQ OMX Copenhagen: ONXEO), an innovative biopharmaceutical company specialized in the development of orphan oncology drugs, today announces the second payment of €1.25 million from BPIFrance (ex OSEO) as a part of the funding granted to support the NICE (Nano Innovation for Cancer) consortium. NICE is the first consortium of nanomedicine stakeholders in France focused on…read more →

BioAlliance Pharma strengthens Livatag® patent protection in Japan until 2032

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced the issuance of a new patent in Japan strengthening the industrial property protection of Livatag® (doxorubicin Transdrug™), currently being developed in primary liver cancer. Livatag® was already patented until 2019 with a first patent family covering the pharmaceutical…read more →

Livatag® receives Fast Track Designation from the FDA for the treatment of primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that Livatag® (doxorubicin Transdrug™) received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the treatment of hepatocellular carcinoma (primary liver cancer) after treatment with Sorafenib. The Fast Track procedure is designed to facilitate interactions…read more →

Quarterly information as of March 31, 2014

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today published a summary of the key events of the first quarter of 2014, as well as its consolidated revenues for the quarter. Key orphan oncology programs Validive® and Livatag® have successfully reached important milestones during the first quarter of…read more →

BioAlliance Pharma announces a new positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company specialized in the development of drugs in orphan oncology diseases, today announced that the European Independent Board of Experts (Data Safety and Monitoring Board, DSMB) in charge of the safety profile of the ReLive Phase III trial, today held its fourth meeting and once more unanimously recommended continuing the study…read more →

Strengthening and extension of the industrial protection of Livatag® until 2031 – First delivery of a new European patent

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology products, announced today a major strengthening of the patent protection for its product Livatag® (doxorubicine Trandrug™), currently in phase III clinical trial in primary liver cancer (ReLive trial). The European Patent Office has issued a new patent family for Livatag® protecting its specific…read more →

Approval to start ReLive (Livatag®) Phase III Clinical Trial in Primary Liver Cancer in the US and Germany

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology and to supportive care products, announces that it has received authorization to start its Phase III ReLive clinical trial in primary liver cancer in the US (IND approval), following the review of the Livatag® development program by the FDA, as well as in…read more →

Quarterly information as of September 30, 2013

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of Orphan Oncology Products and to Supportive Care Products, today published the major key milestones achieved during the third quarter of 2013. July was marked by a successful capital increase which enabled the Company to raise a net amount of €8.4 million and showed strong support…read more →

BioAlliance Pharma announces third positive DSMB recommendation to continue its Phase III clinical trial with Livatag® in primary liver cancer

BioAlliance Pharma SA (Euronext Paris – BIO), an innovative Company dedicated to the development of orphan oncology and to supportive care products, today announced that the International Independent Board of Experts’ Data and Safety Monitoring Board (DSMB), in charge of the safety profile of the ReLive Phase III trial, unanimously recommended continuing the study without modification for the third time…read more →